297 related articles for article (PubMed ID: 34681959)
61. Recent Advances in CRISPR/Cas9 Delivery Strategies.
Yip BH
Biomolecules; 2020 May; 10(6):. PubMed ID: 32486234
[TBL] [Abstract][Full Text] [Related]
62. Efficient CRISPR/Cas9 genome editing with low off-target effects in zebrafish.
Hruscha A; Krawitz P; Rechenberg A; Heinrich V; Hecht J; Haass C; Schmid B
Development; 2013 Dec; 140(24):4982-7. PubMed ID: 24257628
[TBL] [Abstract][Full Text] [Related]
63. Research Progress on Nanoparticles-Based CRISPR/Cas9 System for Targeted Therapy of Tumors.
Nie D; Guo T; Yue M; Li W; Zong X; Zhu Y; Huang J; Lin M
Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139078
[TBL] [Abstract][Full Text] [Related]
64. Delivery approaches for CRISPR/Cas9 therapeutics in vivo: advances and challenges.
Luther DC; Lee YW; Nagaraj H; Scaletti F; Rotello VM
Expert Opin Drug Deliv; 2018 Sep; 15(9):905-913. PubMed ID: 30169977
[TBL] [Abstract][Full Text] [Related]
65. A review of emerging physical transfection methods for CRISPR/Cas9-mediated gene editing.
Fajrial AK; He QQ; Wirusanti NI; Slansky JE; Ding X
Theranostics; 2020; 10(12):5532-5549. PubMed ID: 32373229
[TBL] [Abstract][Full Text] [Related]
66. Latest Developed Strategies to Minimize the Off-Target Effects in CRISPR-Cas-Mediated Genome Editing.
Naeem M; Majeed S; Hoque MZ; Ahmad I
Cells; 2020 Jul; 9(7):. PubMed ID: 32630835
[TBL] [Abstract][Full Text] [Related]
67. Nonviral Nanoparticles for CRISPR-Based Genome Editing: Is It Just a Simple Adaption of What Have Been Developed for Nucleic Acid Delivery?
Qiu M; Glass Z; Xu Q
Biomacromolecules; 2019 Sep; 20(9):3333-3339. PubMed ID: 31342740
[TBL] [Abstract][Full Text] [Related]
68. Biologically produced and metal-organic framework delivered dual-cut CRISPR/Cas9 system for efficient gene editing and sensitized cancer therapy.
Yu J; Tang M; Zhou Z; Wei Z; Wan F; Hou S; Li Q; Li Y; Tian L
Acta Biomater; 2024 Apr; 178():296-306. PubMed ID: 38417646
[TBL] [Abstract][Full Text] [Related]
69. CRISPR-Cas9 system: A new-fangled dawn in gene editing.
Gupta D; Bhattacharjee O; Mandal D; Sen MK; Dey D; Dasgupta A; Kazi TA; Gupta R; Sinharoy S; Acharya K; Chattopadhyay D; Ravichandiran V; Roy S; Ghosh D
Life Sci; 2019 Sep; 232():116636. PubMed ID: 31295471
[TBL] [Abstract][Full Text] [Related]
70. Lentiviral Vectors for Delivery of Gene-Editing Systems Based on CRISPR/Cas: Current State and Perspectives.
Dong W; Kantor B
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372494
[TBL] [Abstract][Full Text] [Related]
71. Progress of delivery methods for CRISPR-Cas9.
Yang W; Yan J; Zhuang P; Ding T; Chen Y; Zhang Y; Zhang H; Cui W
Expert Opin Drug Deliv; 2022 Aug; 19(8):913-926. PubMed ID: 35818792
[TBL] [Abstract][Full Text] [Related]
72. Cationic Polymer-Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing.
Zhang Z; Wan T; Chen Y; Chen Y; Sun H; Cao T; Songyang Z; Tang G; Wu C; Ping Y; Xu FJ; Huang J
Macromol Rapid Commun; 2019 Mar; 40(5):e1800068. PubMed ID: 29708298
[TBL] [Abstract][Full Text] [Related]
73. Boosting targeted genome editing using the hei-tag.
Thumberger T; Tavhelidse-Suck T; Gutierrez-Triana JA; Cornean A; Medert R; Welz B; Freichel M; Wittbrodt J
Elife; 2022 Mar; 11():. PubMed ID: 35333175
[TBL] [Abstract][Full Text] [Related]
74. Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.
Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Al Abdulmonem W; Moawad AA; Alwanian WM; Almansour NM; Rahmani AH; Khan AA
Int J Nanomedicine; 2023; 18():5531-5559. PubMed ID: 37795042
[TBL] [Abstract][Full Text] [Related]
75. Modern Trends in Plant Genome Editing: An Inclusive Review of the CRISPR/Cas9 Toolbox.
Razzaq A; Saleem F; Kanwal M; Mustafa G; Yousaf S; Imran Arshad HM; Hameed MK; Khan MS; Joyia FA
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31430902
[TBL] [Abstract][Full Text] [Related]
76. Co-delivery of Sorafenib and CRISPR/Cas9 Based on Targeted Core-Shell Hollow Mesoporous Organosilica Nanoparticles for Synergistic HCC Therapy.
Zhang BC; Luo BY; Zou JJ; Wu PY; Jiang JL; Le JQ; Zhao RR; Chen L; Shao JW
ACS Appl Mater Interfaces; 2020 Dec; 12(51):57362-57372. PubMed ID: 33301289
[TBL] [Abstract][Full Text] [Related]
77. Genome Editing with CRISPR-Cas9: Can It Get Any Better?
Haeussler M; Concordet JP
J Genet Genomics; 2016 May; 43(5):239-50. PubMed ID: 27210042
[TBL] [Abstract][Full Text] [Related]
78. Enhanced Cytosolic Delivery and Release of CRISPR/Cas9 by Black Phosphorus Nanosheets for Genome Editing.
Zhou W; Cui H; Ying L; Yu XF
Angew Chem Int Ed Engl; 2018 Aug; 57(32):10268-10272. PubMed ID: 29939484
[TBL] [Abstract][Full Text] [Related]
79. CRISPR/Cas9 gene-editing strategies in cardiovascular cells.
Vermersch E; Jouve C; Hulot JS
Cardiovasc Res; 2020 Apr; 116(5):894-907. PubMed ID: 31584620
[TBL] [Abstract][Full Text] [Related]
80. Rationally designed nanoparticle delivery of Cas9 ribonucleoprotein for effective gene editing.
Chae SY; Jeong E; Kang S; Yim Y; Kim JS; Min DH
J Control Release; 2022 May; 345():108-119. PubMed ID: 35247491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
